Sanara MedTech

SMTIPre-clinical

Fort Worth, United Statessanaramedtech.com

Sanara MedTech is a medical technology company with a mission to improve patient outcomes through advanced healing solutions. The company has a diversified commercial portfolio of surgical biologics and is pioneering a novel bone bioadhesive technology, OsStic™, which received FDA Breakthrough Device Designation in 2023. With a focus on the surgical and orthopedic markets, Sanara leverages clinical education and research to drive adoption of its products.

Market Cap

$62.5M

SMTI · Stock Price

USD 7.0024.00 (-77.42%)

Historical price data

AI Company Overview

Technology Platform

Platform based on advanced biomaterials and extracellular matrices for tissue repair and regeneration, including a novel phosphoserine-based bone bioadhesive (OsStic™) technology.

Funding History

Total raised: $15M

IPO$15MUndisclosedNov 20, 2020

Opportunities

Significant growth opportunity lies in the successful development and commercialization of OsStic™, which addresses a high-failure-rate niche in orthopedic trauma.

Expanding indications and geographic reach for its existing commercial portfolio also presents a clear path for revenue growth.

Risk Factors

Key risks include the failure of OsStic™ in clinical development, intense competition in the medtech space from larger companies with greater resources, and challenges in achieving widespread surgeon adoption and favorable reimbursement for new technologies.

Competitive Landscape

Competes with large orthopedics companies (Stryker, Zimmer) in bone grafts and with numerous regenerative medicine firms. OsStic™'s potential differentiation is its unique adhesive and remodeling properties, offering an advantage over traditional non-remodeling bone cements like PMMA.